You are here

P&T April 2016


Discharge and Pharmacy Requirements to Change

Rules proposed by the Centers for Medicare and Medicaid Services would change discharge policies at hospitals and long-term care facilities and update conditions of participation with a focus on medication reconciliation and pharmacist responsibilities.

ASHP Foundation 2016–2020 Forecast

An American Society of Health-System Pharmacists Research and Education Foundation report predicts trends in health care delivery and financing, drug development and therapeutics, pharmaceutical marketplace, pharmacy workforce, and more.

Vaccine Spotlight

A new combination vaccine condenses the final administration of doses in the series of two recommended childhood vaccinations into a single injection.

Zika virus infection has emerged as the world’s newest health threat, linked to microcephaly in infants and Guillain–Barré syndrome in adults. We address the rapid global spread of this disease, and the prospects for successful prevention and treatment.

Meeting Highlights

Featured topics: benzhydrocodone, hydrocodone, and an opioid taper program.

Meeting Highlights

Featured topics: disruption of the gut microbiome by drugs plus new approaches to depression.

Pipeline Plus

Vasculitis, a group of heterogeneous disorders characterized by inflammation and necrosis of the blood vessels, has but one treatment approved by the Food and Drug Administration. However, six novel biologic candidates are in late-stage development.


Medication Errors

Improving medication safety during transitions in care.

Prescription: Washington

Tighter P&T committee rules proposed for NAIC model act.

Approvals, new indications, regulatory activities, and more

Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey) for combination HIV-1 therapy; dapsone gel, 7.5% (Aczone) for acne vulgaris; extended-release tofacitinib (Xeljanz XR) for rheumatoid arthritis; and brivaracetam (Briviact) for epilepsy

Drug Forecast

Paliperidone palmitate three-month injection (Invega Trinza): the first four-times-a-year, long-acting injectable antipsychotic agent for schizophrenia